ClinicalTrials.gg
Sign In

Hangzhou Highlightll Pharmaceutical Co., Ltd clinical trials

The registry lists 14 studies whose lead sponsor is Hangzhou Highlightll Pharmaceutical Co., Ltd. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 28, 2026.

Our grouping of 1 registry name, not the registry’s. See them and correct one ↓

Get an email when these change. Save the Hangzhou Highlightll Pharmaceutical Co., Ltd studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Pipeline: 2 programmes

Each programme counted once, however many studies or names it has. 2 have a study Hangzhou Highlightll Pharmaceutical Co., Ltd leads, registered in the last two years.

Phase 10
Phase 21
Phase 31
Phase 40approved, new studies

All 1.

Programme
TLL-018Phase 3 · 6 live · Arthritis, Rheumatoid · readout Dec 2026

“Registry” is the highest phase of Hangzhou Highlightll Pharmaceutical Co., Ltd’s own registered studies; Hangzhou Highlightll Pharmaceutical Co., Ltd’s own pipeline document is not read yet. “Next readout” is the earliest primary completion date still ahead among its live studies, as the registry states it (most are estimates). Programmes are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Hangzhou Highlightll Pharmaceutical Co., Ltd’s studies test, most open studies first — 1 drug with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Coming up

3 of Hangzhou Highlightll Pharmaceutical Co., Ltd’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. 1D
  3. J’27
  4. F
  5. M
  6. A
  7. M
  8. 1J
  9. 1J
  10. A
  11. S
  12. O
  13. N

All 3

Add all 3 to your calendar (.ics) → With an account.

All 14 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now536%Not yet recruiting 3 · Recruiting 1 · Enrolling by invitation 1
  • Under way, not recruiting214%
  • Completed750%

Phase

  • Phase 27
  • Phase 16
  • Phase 34

Where

  • China11
  • United States1

Over the years

  1. 22
  2. 23
  3. 24
  4. 25
  5. 526

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Hangzhou Highlightll Pharmaceutical Co., Ltd.

  • Hangzhou Highlightll Pharmaceutical Co., Ltd
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    14 studies

Studies

Recruiting first, then most recently updated. Showing 14 of 14.